Every Form 4 that Jasper Therapeutics, Inc. (JSPR) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow JSPR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full JSPR filings page.
Jasper Therapeutics, Inc. reported that director Thomas G. Wiggans received an automatic grant of a stock option covering 7,500 shares of Voting Common Stock at an exercise price of $0.6300 per share. The option expires on 2036-07-31 and, under the Non-Employee Director Compensation Policy, vests in full on the first anniversary of the 2026-07-31 grant date, subject to his continued board service.
Jasper Therapeutics director Lucas Svetlana received an automatic grant of stock options covering 7,500 shares of Voting Common Stock. The options were awarded under the Non-Employee Director Compensation Policy at an exercise price of $0.6300 per share, vesting in full on the first anniversary of the grant, and leave Lucas holding 7,500 derivative securities.
Crutcher Patrick J reported acquisition or exercise transactions in this Form 4 filing.
Jasper Therapeutics, Inc. reported that director Patrick J. Crutcher received a stock option for 7,500 shares of Voting Common Stock on July 31, 2026, exercisable at $0.63 per share. The option vests in full one year after grant, subject to continued service, and expires July 31, 2036, leaving him holding 7,500 options directly.
Jasper Therapeutics, Inc. reported that director Kurt Von Emster received a grant of stock options covering 7,500 shares of Voting Common Stock at an exercise price of $0.6300 per share. The options were granted automatically under the Non-Employee Director Compensation Policy, vest on July 31, 2027, and expire on July 31, 2036.
Jasper Therapeutics, Inc. reported that director Judith Anne Shizuru received an automatic grant of a stock option for 7,500 shares of Voting Common Stock on July 31, 2026, under the Non-Employee Director Compensation Policy. The option has a $0.63 exercise price, vests in full on July 31, 2027, and expires on July 31, 2036, leaving her with 7,500 options held directly.
Jasper Therapeutics, Inc. reports that Chief Operating Officer Matthew E. Ros purchased 881 shares of Non-Voting Convertible Preferred Stock on July 20, 2026 in a private placement under a securities purchase agreement. Each preferred share is automatically convertible into 61 shares of Voting Common Stock after stockholder approval, subject to a holder-selected 4.9%–19.9% beneficial ownership cap, with no expiration.
Patrick J. Crutcher, a director of Jasper Therapeutics, Inc., acquired 888.0000 shares of Non-Voting Convertible Preferred Stock on July 20, 2026 through a private placement under a securities purchase agreement. After stockholder approval, each preferred share will automatically convert into 61 shares of Voting Common Stock, subject to a beneficial ownership cap between 4.9% and 19.9%. Crutcher was also granted stock options for 15000.0000 shares of Voting Common Stock at a $0.7740 exercise price, vesting 25% after one year and monthly over the following 36 months, contingent on continued service.
Jasper Therapeutics CEO and President Jeetinder Singh Mahal received a stock option covering 500,000 shares of voting common stock on February 6, 2026. The option has an exercise price of $1.35 per share and expires on February 6, 2036.
According to the vesting terms, one quarter of the option vests on February 6, 2027, with the remaining three quarters vesting in equal monthly installments over the following 36 months, conditioned on continued service with the company.